Latest Breaking News On - Cell engineering - Page 14 : comparemela.com

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today.

New yorkUnited statesUnited kingdomSaudi arabiaJason kellyCenters for diseaseHoldings incGinkgo bioworks holdings incPrnewswire ginkgo bioworks holdings incExchange commissionGinkgo enzyme servicesCell programsBioworks holdingsTraveler based genomic surveillanceDisease controlAfrican risk

First fully human ovarian organoids provide insights about female reproductive health and disease

Despite the fact that we all start out as an egg cell in one of our mother's ovaries, these human reproductive organs are surprisingly under-studied.

United statesGaryk brixiRichie kohmanPatrick fortunaChristian krammeEmily hendersonToshi shiodaEdward dongPranam chatterjeeEmma tysingerAlina suMerrick pierson smelaDon ingberJessica adamsGeorge churchMutsumi kobayashi

Gameto licenses Wyss Institute s technology for growing

First fully human ovarian organoids could be used to develop new treatments for women’s reproductive health.

United statesMerrick pierson smelaDon ingberPatrick fortunaJessica adamChristian krammeGeorge churchWyss instituteHarvard office of technology developmentHarvard medical schoolHarvard johna paulson school of engineeringDuke universityBiologically inspired engineeringHarvard universityTechnology developmentVice president

Gameto licenses Wyss Institute s technology for growing human ovaries from Harvard University

Gameto licenses Wyss Institute s technology for growing human ovaries from Harvard University
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGaryk brixiRichie kohmanPatrick fortunaChristian krammeToshi shiodaEdward dongPranam chatterjeeEmma tysingerAlina suMerrick pierson smelaDon ingberJessica adamsGeorge churchMutsumi kobayashiWyss center

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic ModelsSAN DIEGO, Dec. . | December 13, 2022

San diegoUnited statesKarl johan malmbergBarbara friedmanMichels sadelainBob valamehrChristina tartagliaMaksim mamonkinCompany phaseStern investor relations incDrug administrationExchange commissionFate therapeutics incAmerican society of hematologyBaylor college of medicineMemorial sloan kettering cancer center